Expert Review of Anticancer Therapy最新文献_第2页

Arguments for and against extending the interval between colonoscopies following negative results in colorectal cancer screening.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-12 DOI: 10.1080/14737140.2024.2438074

Michael Hoffmeister, Thomas Heisser, Hermann Brenner

引用次数: 0

Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-12 DOI: 10.1080/14737140.2024.2438067

Manuel Dómine Gómez, Vivek Subbiah, Solange Peters, María Angeles Sala, José Trigo, Luis Paz-Ares, Antonio Nieto Archilla, Javier Gomez Garcia, Cristina Alvarez García, José Antonio López-Vilariño de Ramos, Carmen Kahatt Lopez, Cristian M Fernandez

{"title":"Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer.","authors":"Manuel Dómine Gómez, Vivek Subbiah, Solange Peters, María Angeles Sala, José Trigo, Luis Paz-Ares, Antonio Nieto Archilla, Javier Gomez Garcia, Cristina Alvarez García, José Antonio López-Vilariño de Ramos, Carmen Kahatt Lopez, Cristian M Fernandez","doi":"10.1080/14737140.2024.2438067","DOIUrl":"10.1080/14737140.2024.2438067","url":null,"abstract":"Introduction: Platinum rechallenge is recommended for patients with small cell lung cancer (SCLC) who relapse ≥90 days after completing first-line chemotherapy, although it may not always be the most suitable option.Areas covered: Articles for review were identified via PubMed and ClinicalTrials.gov searches, supplemented with non-indexed publications (e.g. conference abstracts) known to the manufacturer. We examined evidence for platinum re-exposure in patients with sensitive relapsed SCLC, and present lurbinectedin as a potential alternative. The complementary mechanisms of action of lurbinectedin and platinum, owing to opposite sensitivity of SCLC cells, may resensitize tumor cells to platinum. As efficacy outcomes with lurbinectedin are equivalent or better than those with platinum rechallenge and its hematological safety profile is more favorable, achieving maximum dose intensity is more likely. The simpler dosing schedule of lurbinectedin (1 vs 3 days) and lack of need for granulocyte colony-stimulating factor primary prophylaxis lessens treatment burden.Expert opinion: Incorporation of lurbinectedin into therapeutic algorithms for relapsed SCLC has challenged long-established treatment paradigms. Initial evidence indicates that using lurbinectedin after failure of first-line platinum may prolong the platinum-free interval and reserve platinum for later use. Current evidence supports lurbinectedin as a second-line option in patients with sensitive relapsed SCLC.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-15"},"PeriodicalIF":2.9,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-08 DOI: 10.1080/14737140.2024.2433265

Gui-Qiong Xu, Rui You, Chao Lin, Yu-Long Xie, Li-Zhi Liu, Feng Lei, Ming-Yuan Chen

{"title":"Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies.","authors":"Gui-Qiong Xu, Rui You, Chao Lin, Yu-Long Xie, Li-Zhi Liu, Feng Lei, Ming-Yuan Chen","doi":"10.1080/14737140.2024.2433265","DOIUrl":"https://doi.org/10.1080/14737140.2024.2433265","url":null,"abstract":"Background: To identify the diagnosis and treatment strategies by analyzing the clinical characteristics and treatment methods of RNNCLR.Methods: A total of 210 patients pathologically diagnosed with RNNCLR were retrospectively included. Clinical characteristics, MRI features, treatment methods, and survival outcomes were analyzed. Propensity score matching (PSM) analysis was performed to adjust the surgical benefit.Results: Ninety-one patients (43.3%) took a single biopsy, 67 patients (31.9%) underwent repeated biopsies and 52 patients (24.8%) received endoscopic surgery to obtain pathological positive tissues. RNNCLR had characteristic imaging features distinguished from pure radiation necrosis. The interval from the previous radiotherapy was 13.2 (7.0, 23.3) months. The 1-year, 3-year, and 5-year overall survival rates were 59.6%, 32.3%, and 14.6%. Patients with reirradiation, detectable EBV-DNA level, or ICA exposure had a worse prognosis. Overall survival was significantly higher in the endoscopic surgery group than in nonsurgery group after PSM (3-year OS rates, 44.5% vs. 23.9%, p = 0.011).Conclusions: Histopathological diagnosis of RNNCLR needs repeated biopsies or even surgery. Careful analysis of MRI images, correlation with interval time from last radiation, and short-term follow-up may solve the diagnostic dilemmas. Endoscopic surgery results in a survival benefit by completely resecting lesions or removing necrotic tissue to reduce necrosis-related complications.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.9,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

NRF2/KEAP1 signaling inhibitors in gynecologic cancers.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-07 DOI: 10.1080/14737140.2024.2438951

Sonia Fantone, Daniela Marzioni, Giovanni Tossetta

引用次数: 0

Efficacy and safety analysis of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in the treatment of osteosarcoma: a systematic review and meta-analysis. 血管内皮生长因子受体酪氨酸激酶抑制剂（VEGFR-TKIs）治疗骨肉瘤的疗效和安全性分析：系统综述和荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-26 DOI: 10.1080/14737140.2024.2433634

Boya Guan, Zhenhua Ge, Jinhong Zhang, Xin Feng

{"title":"Efficacy and safety analysis of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in the treatment of osteosarcoma: a systematic review and meta-analysis.","authors":"Boya Guan, Zhenhua Ge, Jinhong Zhang, Xin Feng","doi":"10.1080/14737140.2024.2433634","DOIUrl":"https://doi.org/10.1080/14737140.2024.2433634","url":null,"abstract":"Background: Osteosarcoma is a rare and aggressive bone cancer, with targeted therapy using VEGFR-TKIs (Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors) emerging as a promising treatment option.Research design and methods: This meta-analysis evaluated the efficacy and safety of VEGFR-TKIs in osteosarcoma treatment, analyzing studies from PubMed, Embase, Web of Science, and Cochrane databases until 18 September 2023, involving 14 trials with 447 patients.Results: Results indicated that monotherapy with VEGFR-TKIs had an objective response rate(ORR) of 16% (95% CI = 9-24%) and a disease control rate(DCR) of 65% (95% CI = 57-73%). The average progression-free survival(PFS) was 4.27 months(95% CI = 3.21-5.34), with overall survival(OS) at 9.26 months(95% CI = 7.75-10.77). Combined treatments led to an ORR of 7% (95% CI = 2-12%) and a DCR of 71% (95% CI = 54-88%), with PFS of 5.62 months(95% CI = 3.57-7.74) and OS of 11.84 months(95% CI = 9.26-14.43). Treatment-related adverse events occurred in 83% (95% CI = 74-92%), with severe events in 32% (95% CI = 3-61%).Conclusions: In conclusion, VEGFR-TKIs demonstrate effectiveness and tolerability in osteosarcoma treatment, providing significant disease control and survival advantages despite notable adverse event risks.Registration: PROSPERO (CRD42024579648).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.9,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking survival benefits: primary tumor resection in de novo stage IV breast cancer patients. 释放生存优势：对新发 IV 期乳腺癌患者进行原发肿瘤切除术。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-15 DOI: 10.1080/14737140.2024.2428695

Dong Chen, Yue Wang, Yuancan Pan, Boran Zhang, Wentao Yao, Yu Peng, Ganlin Zhang, Xiaomin Wang

{"title":"Unlocking survival benefits: primary tumor resection in de novo stage IV breast cancer patients.","authors":"Dong Chen, Yue Wang, Yuancan Pan, Boran Zhang, Wentao Yao, Yu Peng, Ganlin Zhang, Xiaomin Wang","doi":"10.1080/14737140.2024.2428695","DOIUrl":"10.1080/14737140.2024.2428695","url":null,"abstract":"Background: For patients with de novo stage IV breast cancer (BC), the conditions under which the primary tumor resection (PTR) may offer benefit remain unclear.Methods: The SEER database provides treatment data for patients with de novo stage IV BC. We screened cases of metastatic BC diagnosed from 2010 to 2015, with primary endpoints of overall survival (OS) and cancer-specific survival (CSS).Results: 9252 patients with stage IV de novo BC were enrolled. For OS, median survival time (MST) was 38 months with systematic treatment (ST) compared to 52 months with ST plus PTR (p < 0.001). For CSS, MST was 38 months for ST versus 54 months for ST plus PTR (p < 0.001). The results of the Cox proportional hazards regression analysis regarding PTR, for OS: bone metastasis (aHR 0.664, 95%CI 0.583-0.756, p < 0.001); liver-lung metastasis (aHR 0.528, 95%CI 0.327-0.853, p = 0.009). For CSS: bone metastasis (aHR 0.655, 95%CI 0.571-0.751, p < 0.001); liver-lung metastasis (aHR 0.549, 95%CI 0.336-0.889, p = 0.017). Kaplan-Meier analysis indicated that in patients with bone metastases and liver-lung metastases, PTR could improve survival outcomes.Conclusion: Liver-lung metastases and bone metastases in patients with de novo stage IV BC could enhance both OS and CSS through PTR.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.9,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statin use and ovarian cancer outcomes. 他汀类药物的使用与卵巢癌的结果。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-10 DOI: 10.1080/14737140.2024.2426551

John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein

{"title":"Statin use and ovarian cancer outcomes.","authors":"John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein","doi":"10.1080/14737140.2024.2426551","DOIUrl":"10.1080/14737140.2024.2426551","url":null,"abstract":"Introduction: Ovarian cancer contributed to 13,270 patient deaths in the United States during 2023 and is considered the most aggressive gynecologic malignancy. While surgery, chemotherapy and targeted medications have improved ovarian cancer patient outcomes, novel therapies that further bolster treatment efficacy without compromising toxicity represent an unmet clinical need.Areas covered: In the current review, we assessed the reported studies involving statin use and ovarian cancer outcomes; a preponderance of the evidence indicated that statins confer a survival benefit in ovarian cancer, especially for patients who underwent treatment post-diagnosis and for a prolonged interval.Expert opinion: The evidence involving a potential survival benefit from statin use in ovarian cancer remains controversial, especially with hydrophilic statins (e.g. pravastatin). While statin users may exhibit better ovarian cancer survival outcomes than non-statin users, additional research should evaluate the putative clinical benefits of statins in ovarian cancer via randomized controlled trials.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-4"},"PeriodicalIF":2.9,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters. 利用免疫组化和临床参数开发宫颈上皮内瘤术后复发预测提名图。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-04 DOI: 10.1080/14737140.2024.2423681

Shikang Qiu, Huihui Jiang, Qiannan Wang, Limin Feng

{"title":"Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters.","authors":"Shikang Qiu, Huihui Jiang, Qiannan Wang, Limin Feng","doi":"10.1080/14737140.2024.2423681","DOIUrl":"10.1080/14737140.2024.2423681","url":null,"abstract":"Background: We aimed to develop a nomogram to predict abnormal follow-up results of co-testing for cytology and human papillomavirus (HPV) in cervical intraepithelial neoplasia (CIN) patients after conization.Research design and methods: Two hundred sixty-three patients initially diagnosed as CIN2+ were recruited. Data on immunohistochemical (IHC) staining scores, along with demographic and clinical information were collected. Using least absolute shrinkage and selection operator (LASSO) regression analysis, variables were identified for inclusion. A predict model and nomogram were developed through multi-factor logistic regression. The goodness-of-fit test was applied across different cohorts to construct the calibration curve of the model, and the predictive effect was evaluated by the receiver operating characteristic curve. Decision curve analysis was performed to determine the net benefit.Results: Five predictor variables, including protein expression score, vaginal infection, HPV coinfection, and cone height were screened and plotted as a nomogram. The calibration curves showed a good fit. The area under the curve of the model was 0.835 for the training cohort and 0.728 for the internal test cohort. The decision curve analysis indicated that the nomogram provides significant net advantages for clinical use.Conclusion: A practical nomogram predict model was developed to predict abnormal follow-up outcomes in CINs after conization.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.9,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of the 21-gene recurrence score testing on chemotherapy selection and clinical outcomes in T3N0 luminal breast cancer. 21基因复发评分测试对T3N0腔隙性乳腺癌化疗选择和临床疗效的影响。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-03 DOI: 10.1080/14737140.2024.2423683

Ke Liu, Jia-Yi Li, Guan-Qiao Li, Zhen-Yu He, San-Gang Wu

{"title":"Impact of the 21-gene recurrence score testing on chemotherapy selection and clinical outcomes in T3N0 luminal breast cancer.","authors":"Ke Liu, Jia-Yi Li, Guan-Qiao Li, Zhen-Yu He, San-Gang Wu","doi":"10.1080/14737140.2024.2423683","DOIUrl":"10.1080/14737140.2024.2423683","url":null,"abstract":"Background: The role of 21-gene recurrence score (RS) testing on chemotherapy decision-making and survival outcomes for T3N0 luminal breast cancer (BC) remains unclear. This study aimed to investigate the effect of RS testing in chemotherapy selection and prognosis in these patients.Research design and methods: Patients diagnosed with T3N0 luminal BC were included from the Surveillance, Epidemiology, and End Results Oncotype database. The likelihood of undergoing chemotherapy was analyzed using the chi-square test and binomial logistic regression. Survival analysis used Kaplan-Meier method and multivariate Cox proportional hazards models.Results: Of the 3186 patients, 852 (26.7%) underwent RS testing. Those who had RS testing demonstrated a lower probability of chemotherapy receipt than those without RS testing (27.0% vs. 47.5%, p < 0.001). Higher RS correlated with increased the probabilities of chemotherapy receipt. The probabilities of chemotherapy for low-risk, intermediate-risk, and high-risk were 9.8%, 26.7%, and 60.6%, respectively (p < 0.001). RS testing independently improved breast cancer-specific survival (p < 0.001) and overall survival (p < 0.001). In the high-risk cohort, chemotherapy administration was associated with improved overall survival than those who did not (p = 0.038).Conclusions: Our study highlights the significant role of RS testing in guiding treatment decisions and improving survival outcomes for patients with T3N0 luminal BC.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.9,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis. 胃癌中 TIMP1 表达的临床病理和预后意义：系统综述和荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-09-24 DOI: 10.1080/14737140.2024.2408278

Mingcan Zheng, Puxu Wang, Yuhang Wang, Zirui Jia, Jiacheng Gao, Xiaodong Tan, Hailong Chen, Guo Zu

{"title":"Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis.","authors":"Mingcan Zheng, Puxu Wang, Yuhang Wang, Zirui Jia, Jiacheng Gao, Xiaodong Tan, Hailong Chen, Guo Zu","doi":"10.1080/14737140.2024.2408278","DOIUrl":"10.1080/14737140.2024.2408278","url":null,"abstract":"Background: The research on the associations between tissue inhibitors of metalloproteinase-1 (TIMP1) expression and the clinicopathological characteristics and prognosis of patients with gastric cancer (GC) have resulted in contradictory findings. Exploring the associations between TIMP1 and clinicopathological parameters and the prognosis of GC patients is essential.Methods: We searched the literature in the databases according to the inclusion and exclusion criteria. Hazard ratios (HRs), odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to evaluate the relationships between TIMP1 expression and the clinicopathological parameters and prognosis of GC patients.Results: Nine studies with 1,200 GC patients were included. Our results indicated that TIMP1 expression was not related to sex, age, TNM stage, depth of invasion, lymph node metastasis, or tumor size in GC patients. However, TIMP1 expression was associated with the differentiation of GC. Furthermore, TIMP1 expression was associated with poor prognosis in GC patients.Conclusion: TIMP1 expression was related to tumor differentiation and poor prognosis but not sex, age, TNM stage, depth of invasion, lymph node metastasis or tumor size.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1169-1176"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0